Spravato is now the first stand-alone therapy for treatment-resistant depression, for patients who haven’t responded to oral ...

Johnson & Johnson surpassed earnings expectations with strong sales, but it faces challenges ahead due to patent expirations.

Intra-Cellular Therapies makes Caplyta, a once-daily pill for adults with schizophrenia and bipolar-related depression ...

Johnson & Johnson executives, on a Wednesday earnings call, did not provide a timeline for when U.S. Varipulse cases will ...

Johnson & Johnson's Q4 2024 earnings missed EPS expectations, but broadly met revenue targets. Click here to read why JNJ ...

Johnson & Johnson said on Wednesday it has temporarily paused the rollout of its Varipulse heart device in the United States, citing an abundance of caution as the company investigates four reported ...

In a report released today, Terence Flynn from Morgan Stanley maintained a Hold rating on Johnson & Johnson (JNJ – Research Report), with a ...

Despite CVS Health's issues, its prospects and solid dividend program make it attractive for income seekers. Johnson & ...

Johnson & Johnson, founded in 1886, makes and sells medical devices, pharmaceuticals, and consumer health products. Headquartered in New Brunswick, N.J., the company operates over 250 subsidiary ...

Leerink Partners analyst Marc Goodman has maintained their bullish stance on JNJ stock, giving a Buy rating on January 8.Stay Ahead of the ...